Search

Your search keyword '"Iftner, Thomas"' showing total 689 results
Start Over Author "Iftner, Thomas"
689 results on '"Iftner, Thomas"'

2. IPVS policy statement on HPV nucleic acid testing guidance for those utilising/considering HPV as primary precancer screening: Quality assurance and quality control issues.

Author

Garland, Suzanne, Iftner, Thomas, Cuschieri, Kate, Kaufmann, Andreas, Arbyn, Marc, de Sanjose, Silvia, Poljak, Mario, Dillner, Joakim, and Unger, Elizabeth

Subjects
Cervical, HPV, Primary, Screening, Validation, Female, Humans, Uterine Cervical Neoplasms, Mass Screening, Papillomavirus Infections, Early Detection of Cancer, Papillomaviridae, Quality Control, Nucleic Acids, Policy
Abstract

We advise that only clinically validated HPV assays which have fulfilled internationally accepted performance criteria be used for primary cervical screening. Further, assays should be demonstrated to be fit for purpose in the laboratory in which they will ultimately be performed, and quality materials manuals and frameworks will be helpful in this endeavor. Importantly, there is a fundamental shortage of well validated, low-cost, low complexity HPV tests that have demonstrated utility in a near-patient setting; representing a significant challenge and focus for future development in order to reach the WHOs goal of eliminating cervical cancer.

Published
2023

4. Detection of circulating cell-free HPV DNA of 13 HPV types for patients with cervical cancer as potential biomarker to monitor therapy response and to detect relapse

Author

Mittelstadt, Suzana, Kelemen, Olga, Admard, Jakob, Gschwind, Axel, Koch, André, Wörz, Sarah, Oberlechner, Ernst, Engler, Tobias, Bonzheim, Irina, Staebler, Annette, Weidner, Nicola, Stubenrauch, Frank, Iftner, Thomas, Riess, Olaf, Schroeder, Christopher, Kommoss, Stefan, and Ossowski, Stephan

Published
2023
Full Text
View/download PDF

5. Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions

Author

Butler, Daniel, Mozsary, Christopher, Meydan, Cem, Foox, Jonathan, Rosiene, Joel, Shaiber, Alon, Danko, David, Afshinnekoo, Ebrahim, MacKay, Matthew, Sedlazeck, Fritz J, Ivanov, Nikolay A, Sierra, Maria, Pohle, Diana, Zietz, Michael, Gisladottir, Undina, Ramlall, Vijendra, Sholle, Evan T, Schenck, Edward J, Westover, Craig D, Hassan, Ciaran, Ryon, Krista, Young, Benjamin, Bhattacharya, Chandrima, Ng, Dianna L, Granados, Andrea C, Santos, Yale A, Servellita, Venice, Federman, Scot, Ruggiero, Phyllis, Fungtammasan, Arkarachai, Chin, Chen-Shan, Pearson, Nathaniel M, Langhorst, Bradley W, Tanner, Nathan A, Kim, Youngmi, Reeves, Jason W, Hether, Tyler D, Warren, Sarah E, Bailey, Michael, Gawrys, Justyna, Meleshko, Dmitry, Xu, Dong, Couto-Rodriguez, Mara, Nagy-Szakal, Dorottya, Barrows, Joseph, Wells, Heather, O’Hara, Niamh B, Rosenfeld, Jeffrey A, Chen, Ying, Steel, Peter AD, Shemesh, Amos J, Xiang, Jenny, Thierry-Mieg, Jean, Thierry-Mieg, Danielle, Iftner, Angelika, Bezdan, Daniela, Sanchez, Elizabeth, Campion, Thomas R, Sipley, John, Cong, Lin, Craney, Arryn, Velu, Priya, Melnick, Ari M, Shapira, Sagi, Hajirasouliha, Iman, Borczuk, Alain, Iftner, Thomas, Salvatore, Mirella, Loda, Massimo, Westblade, Lars F, Cushing, Melissa, Wu, Shixiu, Levy, Shawn, Chiu, Charles, Schwartz, Robert E, Tatonetti, Nicholas, Rennert, Hanna, Imielinski, Marcin, and Mason, Christopher E

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Clinical Sciences, Infectious Diseases, Vaccine Related, Biodefense, Rare Diseases, Emerging Infectious Diseases, Clinical Research, Prevention, Lung, Pneumonia & Influenza, Aetiology, Development of treatments and therapeutic interventions, 2.1 Biological and endogenous factors, 5.1 Pharmaceuticals, Infection, Good Health and Well Being, Adult, Aged, Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Antiviral Agents, COVID-19, COVID-19 Nucleic Acid Testing, Drug Interactions, Female, Gene Expression Profiling, Genome, Viral, HLA Antigens, Host Microbial Interactions, Humans, Male, Middle Aged, Molecular Diagnostic Techniques, New York City, Nucleic Acid Amplification Techniques, Pandemics, RNA-Seq, SARS-CoV-2, COVID-19 Drug Treatment
Abstract

In less than nine months, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) killed over a million people, including >25,000 in New York City (NYC) alone. The COVID-19 pandemic caused by SARS-CoV-2 highlights clinical needs to detect infection, track strain evolution, and identify biomarkers of disease course. To address these challenges, we designed a fast (30-minute) colorimetric test (LAMP) for SARS-CoV-2 infection from naso/oropharyngeal swabs and a large-scale shotgun metatranscriptomics platform (total-RNA-seq) for host, viral, and microbial profiling. We applied these methods to clinical specimens gathered from 669 patients in New York City during the first two months of the outbreak, yielding a broad molecular portrait of the emerging COVID-19 disease. We find significant enrichment of a NYC-distinctive clade of the virus (20C), as well as host responses in interferon, ACE, hematological, and olfaction pathways. In addition, we use 50,821 patient records to find that renin-angiotensin-aldosterone system inhibitors have a protective effect for severe COVID-19 outcomes, unlike similar drugs. Finally, spatial transcriptomic data from COVID-19 patient autopsy tissues reveal distinct ACE2 expression loci, with macrophage and neutrophil infiltration in the lungs. These findings can inform public health and may help develop and drive SARS-CoV-2 diagnostic, prevention, and treatment strategies.

Published
2021

7. IPVS policy statement on HPV nucleic acid testing guidance for those utilising/considering HPV as primary precancer screening: Quality assurance and quality control issues

Author

Garland, Suzanne M, Stanley, Margaret, Moscicki, Anna-Barbara, Woo, Yin Ling, Bhatla, Neerja, Chan, Karen L., Palefsky, Joel, Giuliano, Anna R, Kaufmann, Andreas M, de Sanjose, Silvia, Brotherton, Julia M.L., Feldman, Sarah, Garland, Suzanne M., Iftner, Thomas, Cuschieri, Kate, Arbyn, Marc, Poljak, Mario, Dillner, Joakim, and Unger, Elizabeth R.

Published
2023
Full Text
View/download PDF

12. Robust and durable serological response following pediatric SARS-CoV-2 infection

Author

Renk, Hanna, Dulovic, Alex, Seidel, Alina, Becker, Matthias, Fabricius, Dorit, Zernickel, Maria, Junker, Daniel, Groß, Rüdiger, Müller, Janis, Hilger, Alexander, Bode, Sebastian F. N., Fritsch, Linus, Frieh, Pauline, Haddad, Anneke, Görne, Tessa, Remppis, Jonathan, Ganzemueller, Tina, Dietz, Andrea, Huzly, Daniela, Hengel, Hartmut, Kaier, Klaus, Weber, Susanne, Jacobsen, Eva-Maria, Kaiser, Philipp D., Traenkle, Bjoern, Rothbauer, Ulrich, Stich, Maximilian, Tönshoff, Burkhard, Hoffmann, Georg F., Müller, Barbara, Ludwig, Carolin, Jahrsdörfer, Bernd, Schrezenmeier, Hubert, Peter, Andreas, Hörber, Sebastian, Iftner, Thomas, Münch, Jan, Stamminger, Thomas, Groß, Hans-Jürgen, Wolkewitz, Martin, Engel, Corinna, Liu, Weimin, Rizzi, Marta, Hahn, Beatrice H., Henneke, Philipp, Franz, Axel R., Debatin, Klaus-Michael, Schneiderhan-Marra, Nicole, Janda, Ales, and Elling, Roland

Published
2022
Full Text
View/download PDF

13. Prevalence of Human Papillomavirus (HPV) and HPV Type Distribution in Penile Samples in Young Men in Denmark: Results 10 Years After Implementation of a Girls-Only HPV Vaccination Program.

Author

Munk, Christian, Reinholdt, Kristian, Kjaer, Alexander K, Hemmingsen, Caroline H, Ørnskov, Dorthe, Iftner, Thomas, Waldstrøm, Marianne, and Kjaer, Susanne K

Subjects
HUMAN papillomavirus, HUMAN papillomavirus vaccines, MILITARY service, ODDS ratio, SEXUAL partners
Abstract

Background In Denmark, a girls-only human papillomavirus (HPV) vaccination program was initiated in 2008–2009. The study aim was to assess the HPV prevalence and type distribution in younger men prior to HPV vaccination in men. Methods The study population was younger men who attended information days regarding military service. At random days (2019–2020), 280 men were included. We collected questionnaire data regarding risk factors for HPV infection and a penile swab for HPV testing. We compared results in this study with those from a previous study of young men (2006–2007). Results The majority of participants (94%) were 18–20 years old. The median number of lifetime sexual partners was 4. Altogether, 130 men (46.4%) were HPV positive. No infections with HPV types 6, 11, 16, 18, 31, and 45 were detected. The most frequent type was HPV-51 (detected in 11.1%). Comparison showed that the odds of high-risk HPV type infection were higher in 2019–2020 (prevalence odds ratio [POR], 1.7 [95% confidence interval {CI}, 1.1–2.7]) compared with 2006–2007. In contrast, the odds were lower (POR, 0.3 [95% CI,.1–.6]) for HPV types targeted by the 9-valent HPV vaccine. Conclusions The multicohort girls-only vaccination program has to a large degree protected young men against the HPV types included in the licensed vaccines. This does not speak against gender-neutral vaccination as the HPV prevalence is still high, although consisting largely of less carcinogenic HPV types. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in Households with Children, Southwest Germany, May-August 2020

Author

Stich, Maximilian, Elling, Roland, Renk, Hanna, Janda, Ales, Garbade, Sven F., Muller, Barbara, Krausslich, Hans-Georg, Fabricius, Dorit, Zernickel, Maria, Meissner, Peter, Huzly, Daniela, Grulich-Henn, Jurgen, Haddad, Anneke, Gorne, Tessa, Spielberger, Benedikt, Fritsch, Linus, Nieters, Alexandra, Hengel, Hartmut, Dietz, Andrea N., Stamminger, Thomas, Ganzenmueller, Tina, Ruetalo, Natalia, Peter, Andreas, Remppis, Jonathan, Iftner, Thomas, Jeltsch, Kathrin, Waterboer, Tim, Franz, Axel R., Hoffmann, Georg Friedrich, Engel, Corinna, Debatin, Klaus- Michael, Tonshoff, Burkhard, and Henneke, Philipp

Subjects
Epidemics -- Statistics -- Risk factors -- Germany, Households -- Statistics -- Health aspects, Disease transmission -- Statistics -- Risk factors, Communicable diseases in children -- Statistics -- Risk factors, Pediatric research, Health
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread globally since its emergence in December 2019. As of March 2021, >120 million infections have been reported, and >2.7 million [...]

Published
2021
Full Text
View/download PDF

15. Papillomviren und Polyomaviren

Author

Ganzenmüller, Tina, Iftner, Thomas, Suerbaum, Sebastian, editor, Burchard, Gerd-Dieter, editor, Kaufmann, Stefan H. E., editor, and Schulz, Thomas F., editor

Published
2020
Full Text
View/download PDF

25. Supplementary Slide 3 from Disruption of the Y-Box Binding Protein-1 Results in Suppression of the Epidermal Growth Factor Receptor and HER-2

Author

Wu, Joyce, primary, Lee, Cathy, primary, Yokom, Daniel, primary, Jiang, Helen, primary, Cheang, Maggie C.U., primary, Yorida, Erika, primary, Turbin, Dmitry, primary, Berquin, Isabelle M., primary, Mertens, Peter R., primary, Iftner, Thomas, primary, Gilks, C. Blake, primary, and Dunn, Sandra E., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 1 from Disruption of the Y-Box Binding Protein-1 Results in Suppression of the Epidermal Growth Factor Receptor and HER-2

Author

Wu, Joyce, primary, Lee, Cathy, primary, Yokom, Daniel, primary, Jiang, Helen, primary, Cheang, Maggie C.U., primary, Yorida, Erika, primary, Turbin, Dmitry, primary, Berquin, Isabelle M., primary, Mertens, Peter R., primary, Iftner, Thomas, primary, Gilks, C. Blake, primary, and Dunn, Sandra E., primary

Published
2023
Full Text
View/download PDF

29. Comparison of human papillomavirus-based cervical cancer screening strategies in Tanzania among women with and without HIV

Author

Kahesa, Crispin, Thomsen, Louise T., Linde, Ditte S., Mchome, Bariki, Katanga, Johnson, Swai, Patricia, Manongi, Rachel, Kjaerem, Myassa, Iftner, Thomas, Waldstrøm, Marianne, Mwaiselage, Julius, Rasch, Vibeke, Kjær, Susanne K., Kahesa, Crispin, Thomsen, Louise T., Linde, Ditte S., Mchome, Bariki, Katanga, Johnson, Swai, Patricia, Manongi, Rachel, Kjaerem, Myassa, Iftner, Thomas, Waldstrøm, Marianne, Mwaiselage, Julius, Rasch, Vibeke, and Kjær, Susanne K.

Abstract

Cervical cancer is the most common female cancer in Eastern Africa, and the World Health Organization (WHO) recommends human papillomavirus (HPV)-based screening as a key element to eliminate the disease. In this cross-sectional study from Tanzania, we compared nine HPV-based cervical cancer screening strategies, including HPV testing at standard cut-off; HPV testing at increased viral load cut-offs; HPV testing with partial/extended genotyping, and HPV testing with visual inspection with acetic acid (VIA). We pooled data collected during 2008 to 2009 and 2015 to 2017 from 6851 women aged 25 to 65. Cervical cytology samples were HPV tested with Hybrid Capture 2, and HPV positive samples were genotyped with INNO-LiPA Extra II. Human immunodeficiency virus (HIV) testing and VIA were done according to local standards. We calculated sensitivity, specificity, positive and negative predictive value of screening strategies, with high-grade cytological lesions as reference, separately for women with and without HIV. HPV testing at standard cut-off (1.0 relative light units [RLU]) had highest sensitivity (HIV+: 97.8%; HIV−: 91.5%), but moderate specificity (HIV+: 68.1%; HIV−: 85.7%). Increasing the cut-off for HPV positivity to higher viral loads (5.0/10.0 RLU) increased specificity (HIV+: 74.2%-76.5%; HIV−: 89.5%-91.2%), with modest sensitivity reductions (HIV+: 91.3%-95.7%; HIV−: 83.5%-87.8%). Limiting test positivity to HPV types 16/18/31/33/35/45/52/58 improved specificity while maintaining high sensitivity (HIV+: 90.2%; HIV−: 81.1%). Triage with VIA and/or partial genotyping for HPV16/18 or HPV16/18/45 had low sensitivities (≤65%). In conclusion, HPV testing alone, or HPV testing with extended genotyping or increased viral load cut-offs, may improve cervical cancer screening in Sub-Saharan Africa.

Published
2023

32. Longitudinal Analysis of Humoral and Cellular Immunity in SARS-CoV-2 Exposed Families

Author

Dulovic, Alex, primary, Rabsteyn, Armin, additional, Remppis, Jonathan, additional, Engel, Corinna, additional, Gentzcke, Irene K. E., additional, Mueller, Julia, additional, Tuecks, Nadja, additional, Becker, Matthias, additional, Junker, Daniel, additional, Kaiser, Philipp D., additional, Traenkle, Bjoern, additional, Rothbauer, Ulrich, additional, Walz, Juliane Sarah, additional, Peter, Andreas, additional, Hörber, Sebastian, additional, Ganzenmueller, Tina, additional, Iftner, Thomas, additional, Stich, Maximilian, additional, Toenshoff, Burkhard, additional, Henneke, Philipp, additional, Elling, Roland, additional, Debatin, Klaus-Michael, additional, Janda, Aleš, additional, Schneiderhan-Marra, Nicole, additional, Franz, Axel, additional, Lang, Peter, additional, and Renk, Hanna, additional

Published
2023
Full Text
View/download PDF

35. 2022-RA-1048-ESGO Circulating HPV cell-free DNA in cervical cancer

Author

Mittelstadt, Suzana, primary, Schroeder, Christopher, additional, Kelemen, Olga, additional, Engler, Tobias, additional, Admard, Jakob, additional, Gschwind, Axel, additional, Koch, Andre, additional, Wörz, Sarah Elisabeth, additional, Oberlechner, Ernst, additional, Hoffmann, Sascha, additional, Andress, Jürgen, additional, Neis, Felix, additional, Krämer, Bernhard, additional, Bonzheim, Irina, additional, Staebler, Annette, additional, Stubenrauch, Frank, additional, Iftner, Thomas, additional, Ossowski, Stephan, additional, and Kommoss, Stefan, additional

Published
2022
Full Text
View/download PDF

36. Comparison of human papillomavirus‐based cervical cancer screening strategies in Tanzania among women with and without HIV

Author

Kahesa, Crispin, primary, Thomsen, Louise T., additional, Linde, Ditte S., additional, Mchome, Bariki, additional, Katanga, Johnson, additional, Swai, Patricia, additional, Manongi, Rachel, additional, Kjaerem, Myassa, additional, Iftner, Thomas, additional, Waldstrøm, Marianne, additional, Mwaiselage, Julius, additional, Rasch, Vibeke, additional, and Kjær, Susanne K., additional

Published
2022
Full Text
View/download PDF

46. Persistence and risk factors of high-risk human papillomavirus infection among HIV positive and HIV negative tanzanian women:a cohort study

Author

Swai, Patricia, Rasch, Vibeke, Linde, Ditte S., Mchome, Bariki, Manongi, Rachel, Wu, Chun Sen, Waldstrom, Marianne, Iftner, Thomas, Mwaiselage, Julius, Kjaer, Susanne K., Swai, Patricia, Rasch, Vibeke, Linde, Ditte S., Mchome, Bariki, Manongi, Rachel, Wu, Chun Sen, Waldstrom, Marianne, Iftner, Thomas, Mwaiselage, Julius, and Kjaer, Susanne K.

Abstract

Background: High-risk (HR) human papillomavirus (HPV) persistence is the most important risk factor for cervical cancer. We have assessed the type-specific HR HPV persistence among HIV positive and HIV negative Tanzanian women and factors associated with HR HPV persistence. Methods: In a cohort study including 4080 Tanzanian women, 3074 attended follow-up examination (up to 32 months after enrollment). Cervical samples were obtained for liquid-based cytology and HPV DNA testing using Hybrid Capture 2 and Inno-Lipa Extra II. Information on lifestyle factors was collected through a personal interview. The probability of HR HPV persistence at a given time point since enrollment was estimated non-parametrically using the EMICM algorithm. Results: Among the 462 women HR HPV positive at enrollment, 158 had at least one identical type detected at follow-up. The probability of persistence at 18 months after enrollment was 34.2 (95% CI 29.0–39.4). Stratifying by HIV status, the persistence probability was 42.9% (95% CI 33.5–51.9) among HIV positive, and 28.0% (95% CI 22.1–34.2) among HIV negative. Overall, HR HPV persistence was most common for HPV58, 35, 16, 31, and 52. Among HIV positive women it was HPV45, and HPV16, followed by HPV58 and HPV18, and among HIV negative women it was HPV31, HPV33 and HPV58. Risk factors associated with persistence of HR HPV were older age, longer interval between enrollment and follow-up, binge drinking, and HIV status. Conclusions: HR HPV persistence was common in Tanzania, and most common among HIV positive women. Overall, persistence was most frequent for HPV 58, 35, 16, 31 and 52. The nonavalent HPV vaccine should be considered.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results